Sex and gender are key for precision oncology and benefit all patients
Several misconceptions around sex- and gender-sensitive medicine still limit its application in cancer research and care
Study supports radiomics in predicting immunotherapy effectiveness in advanced NSCLC
In a real-world study, multimodal artificial intelligence models outperform PD-L1 across key endpoints
Next-generation KRAS G12C inhibitor shows promising activity in advanced colorectal cancer
Manageable safety and encouraging antitumour responses were presented with MK-1084 monotherapy and combination regimens
Study provides prospective validation of an alternative biopsy technique
Data shows that index lesion-focused ipsilateral systematic biopsy is not inferior to standard systematic biopsy
AI model boosts survival prediction accuracy after neoadjuvant chemotherapy in breast cancer
A study compared the performance of different models using routinely collected clinicopathological data from women with HR-positive/HER2-negative breast cancer
The power of dual-layer genomics in precision oncology
Integrating DNA and RNA profiling is a promising approach to advance cancer characterisation and guide clinical decision-making
Shaping the use of AI in oncology
ESMO plays a central role in developing long-lasting recommendations for a safe and effective use of artificial intelligence supporting oncology stakeholders
Artificial intelligence is expediting the development of therapeutic immunotherapies
AI-driven approaches can help to design minibinders, which may bring new T-cell receptor-based therapies closer to the clinic
Next-generation PRAME-directed TCR T-cell therapy shows early activity in solid tumours
Tumour reduction was observed with IMA203CD8 across different PRAME-expressing cancers in a phase I trial
Retifanlimab prolongs overall survival in advanced squamous cell anal cancer
Benefits were seen across most predefined subgroups investigated in the practice-changing POD1UM-303/InterAACT-2 study